Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)
Growth Hormone & IGF Research · 2017-10 · 36 · 11-15
DOI: 10.1016/j.ghir.2017.08.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Growth Hormone & IGF Research, 2017-10. Verfasst von Anya Rothenbuhler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology and Diabetes, Centre de Reference des Maladies Rares du Metabolisme du Calcium et du Phophore, Pole I3E, Bicetr…. Hauptthemen laut MEDLINE: Body Height. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
CONTEXT: Twenty-five to 40% of patients with well-controlled X-linked hypophosphatemic rickets (XLHR) have a final height under -2 SDS. Previous studies have shown that recombinant human growth hormone (rhGH) treatment improves linear growth in short children with XLHR. OBJECTIVE: We studied the effectiveness of rhGH treatment in children with XLHR in a larger cohort. DESIGN: Monocentric, prospective, non-randomized trial. SETTING: University hospital in France. PATIENTS: 19 patients with XLHR and a mutation in the PHEX gene. Six male and 6 female Tanner stage 1 patients (age 6.1±2.4years) and 4 male and 3 female Tanner stage 2 patients (age 13.1±1years). At inclusion, height SDS was -2.35±0.8 SDS and growth velocity was -1.12±1.2 SDS. INTERVENTION: 2years of treatment with 67mcg/kg/day of rhGH at initiation. Every three months rhGH dosage was adjusted using an IGF-1 dosing protocol. MAIN OUTCOME MEASURES: Comparison in change from baseline to year 2 in height and growth velocity. RESULTS: Height SDS improved from -2.35±0.8 SDS at baseline, to -1.62±0.8 SDS (p=0.01) after one and to -1.2±1 SDS (p=0.04) after two years of rhGH treatment. There was a strong correlation (r2=0.6104, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology and Diabetes, Centre de Reference des Maladies Rares du Metabolisme du Calcium et du Phophore, Pole I3E, Bicetre Hospital, Paris Sud University, APHP, 94275 Le Kremlin Bicetre, Fran…
- Unite d'Endocrinologie, Maladies Osseuses, Hopital des Enfants, Toulouse University Hospital, INSERM UMR 1043 (CPTP), University of Toulouse Paul Sabatier, Toulouse, France.
- Service de Pediatrie, Centre Hospitalier Regional Universitaire, Hopital Jean Minjoz, Besancon, France.
- Bordeaux, France.
Zitieren
APA
Rothenbuhler, A., Esterle, L., Gueorguieva, I., Salles, J. P., Mignot, B., Colle, M., & Linglart, A. (2017). Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Hormone & IGF Research, 36, 11-15. https://doi.org/10.1016/j.ghir.2017.08.001
Vancouver
Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Hormone & IGF Research. 2017;36:11-15. doi:10.1016/j.ghir.2017.08.001
BibTeX
@article{Rothenbuhler2017,
author = {Rothenbuhler, Anya and Esterle, Laure and Gueorguieva, Iva and Salles, Jean-Pierre and Mignot, Brigitte and Colle, Michel and Linglart, Agnes},
title = {Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)},
journal = {Growth Hormone & IGF Research},
year = {2017},
volume = {36},
pages = {11--15},
doi = {10.1016/j.ghir.2017.08.001}
}
EUVIMED